Gilead signs pact with generic drugmakers in India to expand supply of experimental COVID-19 drug remdesivir
Globally, the virus has infected a total of 4.23 million people as of now while the number of deaths has reached 290000.
Full Article
Gilead signs pact with generic drugmakers in India to expand supply of experimental COVID-19 drug remdesivir
DNA
0 shares
1 views
You might like
Related news coverage
Virus As Bio-Weapon: Contested Origins Of Novel Coronavirus – Analysis
Eurasia Review
By A. Vinod Kumar
“Someone doesn’t have to weaponise the bird flu. The birds are doing that,” says Ellis Cheever..
-
Gilead In Deal With 5 Cos. To Make And Sell Remdesivir In 127 Countries
RTTNews
-
Gilead ties up with generic drugmakers in India, Pakistan for coronavirus COVID-19 drug supply
Zee News
-
Gilead ties up with generic drugmakers for COVID-19 drug supply
Reuters
-
India's Jubilant signs licensing deal for Gilead's COVID-19 drug
Reuters India
Advertisement
More coverage
India's Jubilant signs licensing deal for Gilead's potential COVID-19 drug
India's Jubilant Life Sciences Ltd said on Tuesday it had signed a non-exclusive licensing agreement for selling Gilead Sciences..
Reuters India